Detection of cancer in augmented breasts by positron emission tomography

Eur J Surg. 1999 Sep;165(9):847-51. doi: 10.1080/11024159950189339.

Abstract

Objective: To assess the diagnostic efficiency of positron emission tomography with 18-fluorine fluorodeoxyglucose in detecting breast cancer in augmented breasts.

Design: Retrospective study.

Setting: University hospital, Korea.

Subject: 9 cases or 8 patients with breasts augmented with paraffin or silicone.

Intervention: FDG-PET, mammography, and ultrasonography

Results: The mammogram detected the breast cancer in only 1 of 3 patients, and ultrasonography gave a false positive result in 1 patient with an augmented breast. In contrast, PET predicted all the cancers and 5/6 benign lesions. 2/3 breast cancers had axillary FDG uptake interpreted as showing metastatic involvement, and in 1 case with cancer with no axillary lymph node involvement there was no FDG uptake in the axilla, which correlated with the pathological finding.

Conclusions: Although the high cost of PET makes its use as a screening test for all patients with augmented breasts unrealistic, it would be the best diagnostic choice if other methods failed.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Axilla
  • Breast / diagnostic imaging
  • Breast Implantation
  • Breast Implants*
  • Breast Neoplasms / diagnostic imaging*
  • Female
  • Fluorine Radioisotopes
  • Fluorodeoxyglucose F18
  • Humans
  • Lymph Nodes / diagnostic imaging
  • Lymphatic Metastasis
  • Middle Aged
  • Predictive Value of Tests
  • Radiopharmaceuticals
  • Tomography, Emission-Computed*

Substances

  • Fluorine Radioisotopes
  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18